NSI-189

• CAT Number: I008377
• CAS Number: 1270138-40-3
• Molecular Formula: C₂₂H₃₀N₄O
• Molecular Weight: 366.4998
• Purity: ≥95%
• Synonyms: (4-benzylpiperazin-1-yl)(2-(isopentylamino)pyridin-3-yl)methanone
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone
• InChI: InChI=1S/C22H30N4O/c1-18(2)10-12-24-21-20(9-6-11-23-21)22(27)26-15-13-25(14-16-26)17-19-7-4-3-5-8-19/h3-9,11,18H,10,12-17H2,1-2H3,(H,23,24)
• InChIKey: DYTOQURYRYYNOR-UHFFFAOYSA-N
• SMILES: O=C(N1CCN(CC2=CC=CC=C2)CC1)C3=CC=CN=C3NCCC(C)C

NSI-189 is a neurogenic compound originally developed for the treatment of major depressive disorder (MDD) and cognitive impairments. It is believed to stimulate neurogenesis in the hippocampus, a brain region associated with mood regulation and memory, by promoting the growth of new neurons. NSI-189 has been investigated for its potential to not only alleviate depressive symptoms but also improve cognitive function and overall brain health. Its unique mechanism of action makes it a promising candidate for treating neurodegenerative diseases, depression, and other conditions related to hippocampal dysfunction.

Overview of Clinical Research

Originator Neuralstem
Developer Palisade Bio; University of California, San Diego
Class Antidepressants; Antihyperglycaemics; Neuroprotectants; Nootropics; Piperazines; Pyridines; Small molecules; Vascular disorder therapies
Mechanism of Action Neurogenesis stimulants
Orphan Drug StatusYes – Angelman syndrome
New Molecular Entity Yes
Available For Licensing Yes